Compare Bank Maspion Indonesia Tbk. (BMAS) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank Maspion Indonesia Tbk. vs Dharma Polimetal Tbk. — how do they compare? Bank Maspion Indonesia Tbk. trades at Rp490 (market cap 8.96T, 76.1K 24h volume), while Dharma Polimetal Tbk. trades at Rp985 (market cap 4.64T, 531.1K 24h volume). The key difference: Bank Maspion Indonesia Tbk. is the larger of the two by market cap, and Dharma Polimetal Tbk. is more actively traded (531.1K versus 76.1K). Which is the better fit depends on your goals.
| BMAS | DRMA | |
|---|---|---|
Market Cap | 8.96T | 4.64T |
Volume | 76.1K | 531.1K |
Lot | 761 | 5.31K |
Turnover | 37.5M | 523.32M |
Average Price | 492.76 | 985.35 |
Value | 37.5M | 523.32M |
Indicative Equilibrium Price | 490 | 985 |
Indicative Equilibrium Volume | 99 | 125 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank Maspion Indonesia Tbk.
PT Bank Maspion Indonesia Tbk (the Bank) was established on November 6, 1989 based on Notarial Deed No. 68 of Soetjipto, S.H., which was amended by Notarial Deed No. 49 dated December 5, 1989 of the same notary. The Bank started its commercial operations in 1990. As of December 31, 2012, the Bank has 10 domestic branches, 27 sub-branches, 10 cash offices and 45 Automatic Teller Machines (ATMs) located at Surabaya, Jakarta, Semarang, Denpasar, Medan, Bandung, Makassar, Malang, Solo and Purwokerto.
Read more on BMAS →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
